Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Macgregor

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Pharmacology|October 22, 2010
Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteersJohn P Sabo, Xiuyu Julie Cong, Michael-Friedrich Kraft, et al.
Journal of Clinical Pharmacology|August 14, 2010
Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteersFenglei Huang, Paul Scholl, David B Huang, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavirFenglei Huang, Kristin Drda, Thomas R MacGregor, et al.
Pharmacogenetics and Genomics|August 24, 2011
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapineThorsten Lehr, Jing Yuan, David Hall, et al.
Basic & Clinical Pharmacology & Toxicology|October 28, 2010
Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective studyFenglei Huang, Paul Scholl, David B Huang, et al.
British Journal of Clinical Pharmacology|June 27, 2014
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetesMatthew M Riggs, Leo J Seman, Alexander Staab, et al.
HIV Clinical Trials|November 25, 2005
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN studyBregt S Kappelhoff, Alwin D R Huitema, Frank van Leth, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2008
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)Sharon L Walmsley, Christine Katlama, Adriano Lazzarin, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2007
Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavirLinzhi Chen, John P Sabo, Elsy Philip, et al.
The Pediatric Infectious Disease Journal|January 1, 2014
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over studyCarlo Giaquinto, Gabriel Anabwani, Cornelia Feiterna-Sperling, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Pharmacology|October 22, 2010
Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteersJohn P Sabo, Xiuyu Julie Cong, Michael-Friedrich Kraft, et al.
Journal of Clinical Pharmacology|August 14, 2010
Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteersFenglei Huang, Paul Scholl, David B Huang, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavirFenglei Huang, Kristin Drda, Thomas R MacGregor, et al.
Pharmacogenetics and Genomics|August 24, 2011
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapineThorsten Lehr, Jing Yuan, David Hall, et al.
Basic & Clinical Pharmacology & Toxicology|October 28, 2010
Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective studyFenglei Huang, Paul Scholl, David B Huang, et al.
British Journal of Clinical Pharmacology|June 27, 2014
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetesMatthew M Riggs, Leo J Seman, Alexander Staab, et al.
HIV Clinical Trials|November 25, 2005
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN studyBregt S Kappelhoff, Alwin D R Huitema, Frank van Leth, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2008
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)Sharon L Walmsley, Christine Katlama, Adriano Lazzarin, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2007
Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavirLinzhi Chen, John P Sabo, Elsy Philip, et al.
The Pediatric Infectious Disease Journal|January 1, 2014
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over studyCarlo Giaquinto, Gabriel Anabwani, Cornelia Feiterna-Sperling, et al.
Pageof 3